What Does the Future Hold for Eli Lilly?
GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely the hottest medical sector story in 2024. With its offering of tirzepatide (branded as Mounjaro and Zepbound),
Eli Lilly price target lowered to $1,190 from $1,250 at Citi
Citi analyst Geoff Meacham lowered the firm’s price target on Eli Lilly to $1,190 from $1,250 and keeps a Buy rating on the shares. Ahead of
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 472.57% and currently trading at $756.99. The company has been around since 1876 and the stock didn’t go public until 1952 but in the last 4 years,
Eli Lilly: Market Overreacted
Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas. See why LLY stock is a Buy.
Eli Lilly & Co (LLY) Gets a Buy from Citi
Citi analyst Geoff Meacham maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today. The company’s shares closed last Friday
Eli Lilly (LLY) Stock Drops Despite Market Gains: Important Facts to Note
Eli Lilly (LLY) closed the latest trading day at $804.99, indicating a -0.39% change from the previous session's end. The stock trailed the S&P 500, which registered a daily gain of 0.92%. At the same time,
Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
Eli Lilly trial update on kidney drug hurts Tectonic
Shares of Tectonic Therapeutic (NASDAQ:TECX) plunged on Tuesday after a federal website on clinical trials indicated that Eli Lilly (NYSE:LLY) has terminated a mid-stage trial for its experimental ...
bovnews15h
What Factors Have Led to Eli Lilly And Co (LLY) Stock Trading -16.90% Below Its 52-Week High?
Eli Lilly And Co (LLY) stock saw a modest uptick, ending the day at $808.17 which represents a slight increase of $22.76 or 2.90% from the prior close of $785.41. The stock opened at $780.91 and ...
Eli Lilly & Co. Receives Buy Rating from David Risinger Due to Promising Tirzepatide Trial Results and Competitive Tolerability
Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...
BizTimes1d
Eli Lilly’s planned $3 billion investment in Pleasant Prairie called a ‘watershed moment’ for local economy
On an investment spree with billions of dollars’ worth of projects ongoing globally, Indianapolis-based Eli Lilly and Company ...
Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.
Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.
Eli Lilly Shares Fall After GLP-1 Sales Miss Expectations. Is the Stock in Trouble?
Eli Lilly (NYSE: LLY) has become a beast in healthcare. The excitement surrounding its GLP-1 drugs, Mounjaro and Zepbound, ...
Eli Lilly Appeal Tests Access to Age Bias, Wage Class Litigation
Eli Lilly & Co. on Tuesday will ask the Seventh Circuit to set a standard process for determining when workers can pool ...
Eli Lilly's SWOT analysis: stock poised for growth amid challenges
Eli Lilly and Company (NYSE:LLY), a leading global pharmaceutical firm, finds itself at a pivotal juncture as it navigates a ...